Revefenacin: Completed Phase III enrollment

Theravance completed enrollment in a double-blind, U.S. Phase III safety trial comparing 88 and 175 ug inhaled revefenacin via

Read the full 195 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE